Monday, February 13, 2012

Raptiva pulled from U.S. market

(United Press International) UPDATED 2009-04-09
The U.S. Food and Drug Administration (FDA) is reporting that the maker of the psoriasis drug Raptiva is pulling the drug from the U.S. market. The FDA said the company is taking the action because of a potential risk of patients developing a rare condition known as progressive multifocal leukoencephalopathy (PML). PML is a serious, progressive neurologic disease caused by a virus that affects the central nervous system. FDA officials said doctors are being asked not to start new Raptiva treatment in their patients, and that they should begin discussions with patients using the medication on how to move to other psoriasis treatments.  Read full story >
See all Skin Care News
Related: Raptiva

People who read this also read...

  • How Does Phototherapy Work In Jaundice?
  • Pain Relief For Minor Burn
  • Relief From Sunburn Pain
  • What Kind Of Hpv Does Not Develop Warts?
  • What Do Hpv Warts Look Like?
  • Fluticasone 0.05 Cream